MarketPeel
Insider Trading Intelligence
BL

Benjamin Looker

ESPR
GENERAL COUNSEL · ESPERION THERAPEUTICS, INC. · CIK 0001859509
FILING MIX · LIFETIME52%/48%
BUYS
11
SELLS
10
TOTAL VALUE
$157.3K
COMPANIES
1
ACTIVE SINCE
Jan 2022
HOLDINGS NOW
667,524
AVG SELL PX
$3.23
TRADE KIND
SHOWING 21 / 21
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 15 pending
Forward-return performance of every backtestable P/S trade by Benjamin Looker, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+66.67%+2.23%+0.84%+1.39%-3.38%
14d9+22.22%+4.73%+1.31%+3.42%+5.21%
30d9+33.33%+8.40%+2.48%+5.92%+2.35%
60d9+33.33%+19.91%+3.50%+16.41%+2.69%
90d9+33.33%+23.10%+6.12%+16.98%+9.63%
180d9(2 pending)+71.43%+37.51%+9.11%+28.40%-24.31%
1y9(6 pending)+33.33%+54.74%+23.83%+30.91%+20.39%
2y9(7 pending)+100.00%-47.51%+43.77%-91.28%-91.28%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ESPR · 667,524 shares · as of Jun 17, 2026
0171,264342,528513,792685,0562023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 11 buys / 10 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Legal Officer
11,824$3.16$37.3K667,524Jun 17, 2026Jun 18, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Legal Officer
5,708$2.70$15.4K679,348Mar 17, 2026Mar 18, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,840685,056Mar 13, 2026Mar 16, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
269,230269,230Mar 13, 2026Mar 16, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
1,689$2.88$4.9K384,216Jan 20, 2026Jan 21, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
6,517$3.67$23.9K385,905Dec 17, 2025Dec 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
1,248$2.62$3.3K392,422Oct 17, 2025Oct 20, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
6,267$2.80$17.6K393,670Sep 17, 2025Sep 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
1,304$1.13$1.5K399,937Jul 17, 2025Jul 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
6,422$1.15$7.4K401,241Jun 17, 2025Jun 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
224,000407,663Mar 14, 2025Mar 17, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
201,000201,000Mar 14, 2025Mar 17, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000183,663Mar 14, 2024Mar 15, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Mar 14, 2024Mar 15, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
1,290$1.27$1.6K83,663Apr 19, 2023Apr 20, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,50084,953Mar 14, 2023Mar 15, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
86,90086,900Mar 14, 2023Mar 15, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
General Counsel
6,347$7.00$44.4K64,453Jan 18, 2023Jan 19, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
52,00052,000Jun 7, 2022Jun 9, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,450100,450Jan 27, 2022Jan 28, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,80070,800Jan 27, 2022Jan 28, 2022View →
Other insiders · ESPR
Loading peer insiders…
About this filer
CIK 0001859509
ROLE
General Counsel
PRIMARY
ESPR
COMPANIES
1
ACTIVE SINCE
Jan 2022
MARKETPEEL · /INSIDER/0001859509DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback